한국금융신문

구독신청

'pharmaceutical' 검색결과

Celltrion Fires on All Cylinders with Profitability and Shareholder Returns, but Stock Price Lags Celltrion, which is continuing to break its earnings records, is drawing attention as its corporate value appears to be taking a step backward. Despite a streak of positive drivers—including record-b... 2026-05-22 금요일 | 양현우 기자
Solid Finances, Underwhelming Returns: Yuhan Corporation's Capital Efficiency Challenge An objective assessment of corporate value is only complete when a wide range of variables are considered from multiple angles. The Korea Financial Times uses the Altman Z-Score to evaluate the financ... 2026-05-07 목요일 | 양현우 기자
Samsung Biologics Hits Earnings Peak — But Strike Cloud Dims the Outlook Editor's Note: Corporate value is shaped by a wide range of factors, and an objective assessment requires examining multiple variables. Korea Financial Times explores the current conditions, responses... 2026-04-24 금요일 | 양현우 기자
Celltrion's Share Cancellation Undercut by New Issuance Plan [Treasury Share Report] Celltrion is demonstrating a shareholder-friendly stance by cancelling 9.11 million treasury shares, equivalent to 74% of its total treasury shares holdings. However, despite these shareholder return ... 2026-03-25 수요일 | 양현우 기자
Samsung Biologics Hits Industry-First KRW 2 Trillion Operating Profit, Eyes KRW 3 Trillion Next [KFT Topic] Samsung Biologics has written a new chapter in history. Following its industry-first breakthrough of KRW 1 trillion in operating profit in 2023, the company has reached the KRW 2 trillion milestone ju... 2026-01-23 금요일 | 양현우 기자
Chong Kun Dang's AbClon Bet Delivers Sixfold Gain [KFT Topic] Chong Kun Dang's investment in AbClon is showing signs of hitting the jackpot. As AbClon's share price has surged recently, the current valuation gain exceeds six times the initial investment. Chairma... 2026-01-09 금요일 | 양현우 기자
ABL Bio Eyes Turnaround with 'KRW 4 Trillion Mega-Deal'... Prospects for Additional Deals? ABL Bio has successfully signed a licensing-out (LO) agreement worth approximately KRW 4 trillion for its bispecific antibody platform “Grabody-B,” signaling a turnaround to profitability. The compa... 2025-04-16 수요일 | 김나영 기자
Intensified Competition, Trump Risk, and Oversupply... Samsung Biologics CEO John Rim Faces Mounting Challenges Amid Uncertainty Even as Samsung Biologics (hereinafter referred to as Samsung Bio) continues its strong growth, aiming for annual revenue of KRW 5 trillion this year, uncertainties persist.Former U.S. President Donal... 2025-03-25 화요일 | 김나영 기자
Last Year’s Jackpot, Pharma Firms Bet Everything on the Next Blockbuster Drug Last year marked a significant milestone for South Korea’s pharmaceutical and biotech industry in new drug development. Two domestically developed new drugs were successfully introduced within two ye... 2025-03-05 수요일 | 김나영 기자
K-PharmaBio’s First 'KRW 4 Trillion Club' Member – Samsung Biologics Eyes KRW 5 Trillion with Unmatched Excellence in Capacity Samsung Biologics has rewritten the history of Korea's pharmaceutical and biotech industry with its record-breaking financial performance. The company surpassed KRW 4 trillion in annual revenue for th... 2025-01-24 금요일 | 김나영 기자
'COVID-19 bad times over' Youngjin Pharmaceuticals' operating profit soars 180% last year...'What's the secret to its rapid growth? Youngjin Pharmaceutical is back on a growth trajectory after recovering from the aftermath of COVID-19. For now, the company is focusing on management efficiency, such as sales and custodial business,... 2025-01-20 월요일 | 김나영 기자
GC Group's 3 generations making their presence felt...'uncle-nephew' is gone, 'cousin management' is coming GC Green Cross Group (GC Group) is in the mood to switch from the 'uncle-nephew' system that has been in place for about 10 years to 'cousin management'.According to the pharmaceutical industry on the... 2024-12-23 월요일 | 김나영 기자
K-PharmaBio, Will 20 Years of R&D See the Light?… Expectations for 10th FDA and 1 Trillion Blockbuster Increase↑ The presence of domestic companies in the global pharmaceutical and bio market is growing. There is a series of mentions of blockbuster new drug candidates that are expected to be the 10th domesticall... 2024-12-12 목요일 | 김나영 기자

1

한국금융 포럼 사이버관

더보기

종합 BEST CLICK

Auto&Tech

더보기

FT카드뉴스

더보기

[그래픽 뉴스] 퇴근 후 주차했는데 수익 발생? V2G의 정체

[그래픽 뉴스] “전쟁 신호를 읽는 가장 이상한 방법, 피자 주문량”

[그래픽 뉴스] 트럼프의 ‘타코 한 입’에 흔들린 시장의 비밀

[그래픽 뉴스] 청년정책 5년 계획, 무엇이 달라지나?

[카드뉴스] KT&G, ‘CDP’ 기후변화·수자원 관리 부문 우수기업 선정

더보기

더보기

FT도서

더보기

애드버토리얼

한국금융신문

발행소(주소) : 서울시 중구 다동길 46 다동빌딩 6층 한국금융신문사 ㅣ 사업자번호 : 202-81-39551
제호: 한국금융 ㅣ 발행.편집인 : 김봉국 ㅣ 대표번호 : 02)773-6300
신문사업 등록번호: 서울,다06555 ㅣ 신문사업 등록일자: 1992년 1월 29일 ㅣ 발행.편집인 : 김봉국 ㅣ 발행일자: 1992년 3월2일
인터넷신문 등록번호: 서울, 아03960 ㅣ 인터넷신문 등록·발행: 2015년 11월 3일 ㅣ 청소년보호책임자 : 문수희 실장
FNTIMES.COM의 모든 콘텐츠 및 기사는 저작권법의 보호를 받는 바, 무단 전재, 복사, 배포 등을 금합니다.
Copyrightⓒ 한국금융신문 All Rights Reserved.